The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy
Cancer Res
2009
69 Suppl.
24
598S-599S
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.
J Clin Oncol
2009
27
36
6144-51
Prospective cost analysis from the provider's perspective: pharmaco-economic results from AGO-WSG intergroup adjuvant EC -> DOC trial vs. CMF in nodal-positive breast cancer and its reimbursement
Cancer Res
2009
69 Suppl.
2
380S-380S
Expression differences of proteolytic factors uPA, PAI-1, and seven kallikrein-related peptidases (KLK5, 6, 7, 8, 10, 11, 13) between primary tumor and omentum metastasis impact outcome in advanced ovarian cancer
EJC Suppl
2009
7
4
16-17
The effect of antibacterial acting extracorporeal shockwaves on bacterial cell integrity.
Med Sci Monit
2009
15
12
BR364-9
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Pathol Biol (Paris)
2009
57
6
470-6
Dislocation of Intravenous Port Systems - Three Case Reports
Breast Care (Basel)
2009
4
5
328-331
Endocrinology Fertility preserving measures: the beginning of ovarian stimulation in the production of ooyztes in possible in the luteal phase
Geburtsh Frauenheilk
2009
69
5
420-422
Bisphosphonate compliance protocoll - a study in compiling the influence factors and impact of non-compliance and non-adherence under bisphosphonate therapy
Geburtsh Frauenheilk
2009
69
5
P157 -
Interdisciplinary Consensus on the Use of Adjuvant Bisphosphonate Therapy in Breast Cancer Patients
Geburtsh Frauenheilk
2009
69
6
511-516